Novo's Ozempic OK'd in Europe for type 2 diabetes

|About: Novo Nordisk A/S (NVO)|By:, SA News Editor

As expected, the European Commission approves Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide), a once-weekly human glucagon-like peptide-1 (GLP-1) analogue, for the treatment of adults with type 2 diabetes when metformin is contraindicated or not tolerated.

The advisory group CHMP adopted a positive opinion backing approval in December.

Ozempic was approved in the U.S. in December and in Canada last month.

Previously: European advisory group backs Novo's Ozempic for T2D (Dec. 15, 2017)

Subscribe for full text news in your inbox